Metagenomi Therapeutics, Inc. (MGX): R&D Expense
$94.43M
Year ended 2025-12-31
$88.60M
Trailing 12 months to 2026-06-30
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $94.43M | -13.5% | 2026-03-05, From 2025-01-01 |
| 2024-12-31 | $109.18M | +15.7% | 2026-03-05, From 2024-01-01 |
| 2023-12-31 | $94.40M | n/a | 2025-03-17, From 2023-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Metagenomi Therapeutics, Inc. (MGX) | 2025-12-31 | $94.43M | -13.5% |
| Alector, Inc. (ALEC) | 2025-12-31 | $123.06M | -33.8% |
| Scilex Holding Co (SCLX) | 2025-12-31 | $20.71M | +114.8% |
| LENZ Therapeutics, Inc. (LENZ) | 2025-12-31 | $18.67M | -37.4% |
| Precision Biosciences Inc (DTIL) | 2025-12-31 | $54.17M | -9.0% |
| X4 Pharmaceuticals, Inc (XFOR) | 2025-12-31 | $72.72M | -10.9% |
| C4 Therapeutics, Inc. (CCCC) | 2025-12-31 | $104.24M | -5.8% |
| Pelthos Therapeutics Inc. (PTHS) | 2025-12-31 | $1.23M | +4.2% |
| Kymera Therapeutics, Inc. (KYMR) | 2025-12-31 | $316.57M | +31.8% |
Compare MGX, ALEC, SCLX, LENZ side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗